EMEA Plans To Include Parallel Imports In Future Post-Marketing Tests

The European Medicines Agency (EMEA) plans to screen parallel imports as part of changes to the body's sampling and testing programme for centrally authorised medicinal products (CAPs). This follows proposals in January 2008 for using a risk-based approach for selecting which medicines would be screened in

To read the full article, please sign in or take a free trial.